NovaBridge Biosciences (NBP) Income from Discontinued Operations (2023 - 2024)
NovaBridge Biosciences (NBP) posted quarterly Income from Discontinued Operations of 0.18 for Q2 2024, up 200.0% year-on-year from 0.06 in Q3 2023, and up 238.46% on a QoQ basis from 0.13 in Q3 2023.
NovaBridge Biosciences (NBP) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Income from Discontinued Operations for 2 consecutive years, with 0.18 the latest figure, recorded in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | NovaBridge Biosciences | 397.57 Mn | 397.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 0.18 |
| Sep 30, 2023 | -0.13 |
| Jun 30, 2023 | -0.18 |